StockWatch
·

GLENMARK PHARMACEUTICALS LTD. Q1 FY26 Results

GLENMARKQ1 FY26 Results
Filing
MetricValue ( Cr)vs Q4 FY25
Revenue3.3K0.3%
Total Income3.3K0.7%
Expenditure2.9K0.5%
PBT95.581098.6%
Net Profit46.97971.5%
OPM7.88%2.10pp
NPM1.43%1.30pp
EPS1.66937.5%
View full financials

Glenmark Pharmaceuticals Reports Q1 2025 Results with Profit of INR 3,302.26 Million

14 Aug 2025 · 14 Aug 2025, 05:23 pm

Summary

Glenmark Pharmaceuticals Ltd. has reported its financial results for Q1 2025, ending on 30th June 2025. The company's profit for the quarter is INR 3,302.26 million.

Key Highlights

  1. 1

    Q1 2025 revenue from operations: INR 23,949.28 million

  2. 2

    Profit before tax for Q1 2025: INR 4,011.65 million

  3. 3

    Profit after tax for Q1 2025: INR 3,302.26 million

  4. 4

    Earnings per share (EPS) for Q1 2025: INR 11.70 (basic and diluted)

Management Comments

N

Not provided

The Board at its meeting held today has approved the unaudited financial results for the First Quarter ended 30th June, 2025.

Informational and educational content only. Not investment advice.